Clinical interaction: xenon–propofol combination

The "Clinical interaction: xenon–propofol combination" does not refer to a single molecular target but rather the pharmacological interplay between two distinct anesthetic agents. Xenon is an elemental noble gas that acts primarily as a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, providing anesthesia and significant neuroprotection (PubChem CID 5959). Propofol is a widely used intravenous sedative-hypnotic that functions as a positive allosteric modulator of the gamma-aminobutyric acid type A (GABA-A) receptor (StatPearls, Propofol). Clinical studies have demonstrated that the combination of these two drugs produces an additive or synergistic effect on the depth of hypnosis, typically measured by the Bispectral Index (Rossaint et al., Anesthesiology 2008). This interaction is clinically relevant because it allows for reduced doses of propofol, potentially mitigating its dose-dependent cardiovascular depressive effects while utilizing xenon's hemodynamic stability. Despite these benefits, the combination is primarily a subject of clinical research due to the high cost and specialized equipment required for xenon administration (PubMed PMID 18212568).

Other names

Xenon-propofol interactionXenon-propofol synergyCo-administration of xenon and propofol

Xenon acts as an NMDA receptor antagonist and TREK-1 channel activator, while propofol acts as a GABA-A receptor agonist; their combination results in additive hypnotic effects.